Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$6.51
-0.8%
$6.24
$4.47
$35.98
$7.16M0.9399,915 shs34,939 shs
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$0.25
+5.6%
$0.36
$0.20
$3.89
$7.85M0.941.01 million shs551,055 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.33
-13.1%
$1.92
$0.87
$10.80
$6.38M0.478,399 shs12,038 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.70
-4.2%
$0.80
$0.25
$8.90
$1.82M1.156,298 shs1,921 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%-0.08%-0.91%+27.80%-65.98%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.00%+10.42%-30.62%-50.21%-87.55%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%-11.33%-28.11%-39.48%+132,999,900.00%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-4.18%-18.19%+45.73%-89.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollomics Inc. stock logo
APLM
Apollomics
0.334 of 5 stars
0.05.00.00.00.60.00.0
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.2164 of 5 stars
0.03.00.00.00.60.00.6
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollomics Inc. stock logo
APLM
Apollomics
0.00
N/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollomics Inc. stock logo
APLM
Apollomics
$1.49M4.80N/AN/A$4.48 per share1.45
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/A($2.32) per shareN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K9.64N/AN/A($6.58) per share-0.20
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K4.69N/AN/A($2.59) per share-0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollomics Inc. stock logo
APLM
Apollomics
-$53.86MN/A0.00N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/A-383.58%8/12/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/AN/AN/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollomics Inc. stock logo
APLM
Apollomics
N/A
1.39
1.39
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Apollomics Inc. stock logo
APLM
Apollomics
19.13%
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
Apollomics Inc. stock logo
APLM
Apollomics
N/A
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
6.70%
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollomics Inc. stock logo
APLM
Apollomics
451.10 millionN/ANot Optionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
3831.79 million20.04 millionN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex director resigns, no disagreement cited
Vaccinex to delist common stock from Nasdaq
Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval
Vaccinex receives delisting notification from Nasdaq
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex Shares Tumble 63% On Nasdaq Delisting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apollomics stock logo

Apollomics NASDAQ:APLM

$6.50 -0.06 (-0.84%)
Closing price 07/3/2025 02:27 PM Eastern
Extended Trading
$6.10 -0.40 (-6.15%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$0.25 +0.01 (+5.60%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$0.24 0.00 (-0.81%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.33 -0.20 (-13.07%)
As of 07/3/2025 12:46 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.70 -0.03 (-4.18%)
As of 07/3/2025 12:42 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.